| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02836821 | Neoplasms | Drug: Apatinib Mesylate Tablets|Drug: Rifampicin Capsules | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | 2016-05-01 | 2017-02-23 |
| NCT02995187 | Small Cell Lung Cancer | Drug: Apatinib Mesylate tablet | Chinese Academy of Medical Sciences | Phase 2 | 2016-12-01 | 2016-12-14 |
| NCT02829385 | Colorectal Neoplasms | Drug: Apatinib and XELOX combined treatment group | Shoucheng Ma|LanZhou University | Phase 2 | 2016-06-01 | 2016-07-11 |
| NCT02544737 | Esophageal Cancer|Metastatic Esophageal Cancer|Apatinib | Drug: Apatinib | Hangzhou Cancer Hospital | Phase 2 | 2015-09-01 | 2016-08-25 |
| NCT02772029 | Hepatocellular Carcinoma | Drug: Apatinib Mesylate Tablets | The First Affiliated Hospital of Zhengzhou University | Phase 1|Phase 2 | 2016-05-01 | 2016-05-12 |
| NCT02515435 | Non-Small Cell Lung Cancer | Drug: apatinib single agent | Tongji University | Phase 2 | 2015-01-01 | 2015-07-31 |
| NCT02540824 | Non-small Cell Lung Cancer | Drug: Apatinib single agent arm | Tongji University | Phase 2 | 2015-01-01 | 2015-09-03 |
| NCT02726854 | Pancreatic Neoplasms | Drug: Apatinib | First Affiliated Hospital Xi'an Jiaotong University | Phase 2 | 2016-04-01 | 2016-11-30 |
| NCT03046979 | Hepatocellular Carcinoma | Drug: Apatinib | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | 2016-12-01 | 2017-02-06 |
| NCT02836171 | Neoplasms | Drug: Apatinib Mesylate Tablets|Drug: Itraconazole Capsules | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | 2016-07-01 | 2017-02-23 |
| NCT03083041 | Carcinoma, Non-Small-Cell Lung | Biological: SHR-1210|Drug: Apatinib | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | 2017-03-01 | 2017-03-13 |
| NCT02989259 | Head and Neck Neoplasms | Drug: Apatinib | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | 2016-12-01 | 2016-12-11 |
| NCT02485015 | Stomach Neoplasms | Biological: Cytokine-Induced Killer Cells|Drug: Apatinib | The First People's Hospital of Changzhou | Phase 2 | 2015-06-01 | 2016-02-18 |
| NCT02493582 | Adenocarcinoma of Lung | Biological: Cytokine-Induced Killer Cells|Drug: Apatinib | The First People's Hospital of Changzhou | Phase 2 | 2015-07-01 | 2016-02-04 |
| NCT01653561 | Breast Neoplasms | Drug: Apatinib | Fudan University|Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | 2011-11-01 | 2013-12-02 |
| NCT02878057 | Breast Cancer | Drug: Apatinib | Beijing Cancer Hospital|Hebei Medical University Fourth Hospital|Peking University First Hospital|Peking University Third Hospital|Shanxi Province Cancer Hospital | Phase 2 | 2016-05-01 | 2016-08-24 |
| NCT03007446 | Gastric Cancer | Drug: Apatinib|Drug: Oxaliplatin|Drug: S-1 | Chinese PLA General Hospital | Phase 2 | 2016-11-01 | 2016-12-29 |
| NCT02537171 | Gastric Cancer | Drug: apatinib | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Phase 3 | 2015-07-01 | 2016-08-01 |
| NCT02711007 | Osteosarcoma|Metastasis | Drug: apatinib | GUO WEI|Peking University People's Hospital | Phase 2|Phase 3 | 2016-03-01 | 2016-03-16 |
| NCT02774200 | Metastatic Renal Cell Carcinoma | Drug: Apatinib | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | 2016-05-01 | 2016-05-12 |
